You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
東陽光藥(01558.HK):阿奇黴素片獲批准上市
格隆匯 03-08 19:45

格隆匯3月8日丨東陽光藥(01558.HK)公佈,公司從廣東東陽光藥業有限公司收購的產品阿奇黴素片(規格:0.25g及0.5g)已獲中國國家藥品監督管理局審批完畢並獲准上市。該產品的上市許可持有人為公司的全資子公司東莞市陽之康醫藥有限責任公司。

阿奇黴素片為全身用抗菌藥,主要用於治療敏感細菌所導致的感染,如支氣管炎、肺炎等下呼吸道感染、皮膚和軟組織感染、急性中耳炎、鼻竇炎、咽炎、扁桃體炎等上呼吸道感染。

阿奇黴素是《國家基本醫療保險、工傷保險和生育保險藥品目錄》二零二一年版中的甲類品種,同時是《國家基本藥物目錄》二零一八年版中的品種。根據艾美仕中國市場數據,2020年中國阿奇黴素藥物的銷售額約為1.8億美元。

阿奇黴素片具有良好的臨牀應用價值和市場前景,上市後將成為公司在抗感染疾病治療領域的產品之一,在進一步豐富集團的產品組合的同時,也為廣大患者提供質價雙優的用藥選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.
uSMART
Wealth Growth Made Easy
Open Account